Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1985 4
1987 3
1988 2
1989 3
1990 4
1991 13
1992 3
1993 4
1994 2
1995 7
1996 7
1997 12
1998 11
1999 12
2000 4
2001 7
2002 9
2003 8
2004 6
2005 6
2006 8
2007 3
2008 9
2009 13
2010 12
2011 7
2012 9
2013 11
2014 7
2015 8
2016 13
2017 18
2018 17
2019 19
2020 22
2021 27
2022 22
2023 28
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Results by year

Filters applied: . Clear all
Page 1
Current concepts in the management of diabetic polyneuropathy.
Ziegler D, Papanas N, Schnell O, Nguyen BDT, Nguyen KT, Kulkantrakorn K, Deerochanawong C. Ziegler D, et al. J Diabetes Investig. 2021 Apr;12(4):464-475. doi: 10.1111/jdi.13401. Epub 2020 Oct 11. J Diabetes Investig. 2021. PMID: 32918837 Free PMC article. Review.
Among pathogenesis-oriented treatments, alpha-lipoic acid, actovegin, benfotiamine and epalrestat are currently authorized to treat DSPN in several countries. ...
Among pathogenesis-oriented treatments, alpha-lipoic acid, actovegin, benfotiamine and epalrestat are currently authorized to treat D …
Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase.
Shi W, Xu G, Gao Y, Zhao J, Liu T, Zhao J, Yang H, Wei Z, Li H, Xu AL, Bai Z, Xiao X. Shi W, et al. J Transl Med. 2023 Oct 7;21(1):700. doi: 10.1186/s12967-023-04380-4. J Transl Med. 2023. PMID: 37805545 Free PMC article.
Next, MCD-induced NASH models were used to evaluate the therapeutic effects of epalrestat in vivo. In addition, to evaluate the safety of epalrestat in vivo, mice were gavaged with epalrestat daily for 14 days. ...Importantly, epalrestat exerts its inh …
Next, MCD-induced NASH models were used to evaluate the therapeutic effects of epalrestat in vivo. In addition, to evaluate the safet …
Mannose metabolism normalizes gut homeostasis by blocking the TNF-α-mediated proinflammatory circuit.
Xiao P, Hu Z, Lang J, Pan T, Mertens RT, Zhang H, Guo K, Shen M, Cheng H, Zhang X, Cao Q, Ke Y. Xiao P, et al. Cell Mol Immunol. 2023 Feb;20(2):119-130. doi: 10.1038/s41423-022-00955-1. Epub 2022 Dec 5. Cell Mol Immunol. 2023. PMID: 36471112 Free PMC article.
Additionally, we found dysregulated mannose metabolism in the colonic mucosa of patients with inflammatory bowel disease. Finally, we revealed that activating PMM2 activity with epalrestat, a clinically approved drug for the treatment of diabetic neuropathy, elicited furth …
Additionally, we found dysregulated mannose metabolism in the colonic mucosa of patients with inflammatory bowel disease. Finally, we reveal …
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ligezka AN, Radenkovic S, Saraswat M, Garapati K, Ranatunga W, Krzysciak W, Yanaihara H, Preston G, Brucker W, McGovern RM, Reid JM, Cassiman D, Muthusamy K, Johnsen C, Mercimek-Andrews S, Larson A, Lam C, Edmondson AC, Ghesquière B, Witters P, Raymond K, Oglesbee D, Pandey A, Perlstein EO, Kozicz T, Morava E. Ligezka AN, et al. Ann Neurol. 2021 Dec;90(6):887-900. doi: 10.1002/ana.26245. Epub 2021 Oct 26. Ann Neurol. 2021. PMID: 34652821 Free PMC article.
METHODS: We performed PMM enzyme measurements, multiplexed proteomics, and glycoproteomics in PMM2-deficient fibroblasts before and after epalrestat treatment. Safety and efficacy of 0.8 mg/kg/day oral epalrestat were studied in a child with PMM2-CDG for 12 months. …
METHODS: We performed PMM enzyme measurements, multiplexed proteomics, and glycoproteomics in PMM2-deficient fibroblasts before and after …
Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer.
Zhang KR, Zhang YF, Lei HM, Tang YB, Ma CS, Lv QM, Wang SY, Lu LM, Shen Y, Chen HZ, Zhu L. Zhang KR, et al. Sci Transl Med. 2021 Oct 6;13(614):eabg6428. doi: 10.1126/scitranslmed.abg6428. Epub 2021 Oct 6. Sci Transl Med. 2021. PMID: 34613810
Suppression of AKR1B1 with selective inhibitors, including the clinically approved antidiabetic drug epalrestat, restored the sensitivity of resistant cell lines to EGFR TKIs and delayed resistance in lung cancer patient-derived xenograft mice. ...
Suppression of AKR1B1 with selective inhibitors, including the clinically approved antidiabetic drug epalrestat, restored the sensiti …
Pathogenetic treatments for diabetic peripheral neuropathy.
Ziegler D. Ziegler D. Diabetes Res Clin Pract. 2023 Dec;206 Suppl 1:110764. doi: 10.1016/j.diabres.2023.110764. Diabetes Res Clin Pract. 2023. PMID: 38245327 Free article. Review.
Efficacy and excellent safety were demonstrated in several meta-analyses (alpha-lipoic acid) and randomized clinical trials (benfotiamine, actovegin, epalrestat) in the treatment of symptomatic DPN. The NATHAN 1 trial demonstrated an improvement of neuropathic signs (defic …
Efficacy and excellent safety were demonstrated in several meta-analyses (alpha-lipoic acid) and randomized clinical trials (benfotiamine, a …
The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia.
Zhang T, Wu J, Yao X, Zhang Y, Wang Y, Han Y, Wu Y, Xu Z, Lan J, Han S, Zou H, Sun Q, Wang D, Zhang J, Wang G. Zhang T, et al. Mol Neurobiol. 2023 Jul;60(7):3741-3757. doi: 10.1007/s12035-023-03304-z. Epub 2023 Mar 20. Mol Neurobiol. 2023. PMID: 36940077 Free PMC article.
Thus, we hypothesized that the protective effect of epalrestat is mainly related to regulating the survival of BMVECs and tight junction protein levels after cerebral ischemia. To test this hypothesis, a mouse model of cerebral ischemia was established by permanent middle …
Thus, we hypothesized that the protective effect of epalrestat is mainly related to regulating the survival of BMVECs and tight junct …
Tracer metabolomics reveals the role of aldose reductase in glycosylation.
Radenkovic S, Ligezka AN, Mokashi SS, Driesen K, Dukes-Rimsky L, Preston G, Owuocha LF, Sabbagh L, Mousa J, Lam C, Edmondson A, Larson A, Schultz M, Vermeersch P, Cassiman D, Witters P, Beamer LJ, Kozicz T, Flanagan-Steet H, Ghesquière B, Morava E. Radenkovic S, et al. Cell Rep Med. 2023 Jun 20;4(6):101056. doi: 10.1016/j.xcrm.2023.101056. Epub 2023 May 30. Cell Rep Med. 2023. PMID: 37257447 Free PMC article.
Recently, abnormal polyol metabolism has been implicated in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG) and an AR inhibitor, epalrestat, proposed as a potential therapy. Considering that the PMM2 enzyme is not directly involved in polyol metabolism …
Recently, abnormal polyol metabolism has been implicated in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG) and an AR i …
Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
Steele JW, Faulds D, Goa KL. Steele JW, et al. Drugs Aging. 1993 Nov-Dec;3(6):532-55. doi: 10.2165/00002512-199303060-00007. Drugs Aging. 1993. PMID: 8312678 Review.
Epalrestat is a carboxylic acid derivative which inhibits aldose reductase, an enzyme of the sorbitol (polyol) pathway. ...Comparisons with other aldose reductase inhibitors are also required to fully determine the role of epalrestat. The suggested ability of epa …
Epalrestat is a carboxylic acid derivative which inhibits aldose reductase, an enzyme of the sorbitol (polyol) pathway. ...Comparison …
N-Acetylcysteine overcomes epalrestat-mediated increase of toxic 4-hydroxy-2-nonenal and potentiates the anti-arthritic effect of epalrestat in AIA model.
Wang L, Huang B, Zeng Y, Yang J, Li Z, Ng JPL, Xu X, Su L, Yun X, Qu L, Chen R, Luo W, Wang Y, Chen C, Yang L, Qu Y, Zhang W, Chan JTW, Wang X, Law BYK, Mok SWF, Chung SK, Wong VKW. Wang L, et al. Int J Biol Sci. 2023 Aug 6;19(13):4082-4102. doi: 10.7150/ijbs.85028. eCollection 2023. Int J Biol Sci. 2023. PMID: 37705749 Free PMC article.
Epalrestat, an aldose reductase inhibitor (ARI), has been clinically adopted in treating diabetic neuropathy in China and Japan. ...Co-treatment with NAC significantly reversed epalrestat-induced upregulation of 4-HNE level and potentiated the anti-arthritic effect …
Epalrestat, an aldose reductase inhibitor (ARI), has been clinically adopted in treating diabetic neuropathy in China and Japan. ...C …
353 results